Potent activity of indolequinones against human pancreatic cancer: Identification of thioredoxin reductase as a potential target

Molecular Pharmacology

Volumn 76, Issue 1, 2009, Pages 163-172

  Yan, Chao ^a   Shieh, Biehuoy ^a   Reigan, Philip ^a   Zhang, Zhiyong ^b   Colucci, Marie A ^c   Chilloux, Aurélie ^c   Newsome, Jeffery J ^d   Siegel, David ^a   Chan, Dan ^b   Moody, Christopher J ^c   Ross, David ^a,e  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d UNIVERSITY OF EXETER   (United Kingdom)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYMETHYL 5 METHOXY 1 METHYL 3 [(2,4,6 TRIFLUOROPHENOXY)METHYL]INDOLE 4,7 DIONE; 2 HYDROXYMETHYL 5 METHOXY 1 METHYL 3 [(4 NITROPHENOXY)METHYL]INDOLE 4,7 DIONE; 2 HYDROXYMETHYL 6 METHOXY 1 METHYL 3 [(4 NITROPHENOXY)METHYL]INDOLE 4,7 DIONE; 5 METHOXY 1 METHYL 3 [(2,4,6 TRIFLUOROPHENOXY)METHYL]INDOLE 4,7 DIONE; 5 METHOXY 1 METHYL 3 [(4 NITROPHENOXY)METHYL]INDOLE 4,7 DIONE; 5 METHOXY 1,2 DIMETHYL 3 [(4 NITROPHENOXY)METHYL]INDOLE 4,7 DIONE; 5 METHOXY 1,2 DIMETHYL 3 [1 OXO 2 (2,4,6 TRIFLUOROPHENOXY)ETHYL]INDOLE 4,7 DIONE; 6 METHOXY 1 METHYL 3 [(2,4,6 TRIFLUOROPHENOXY)METHYL]INDOLE 4,7 DIONE; 6 METHOXY 1 METHYL 3 [(4 NITROPHENOXY)METHYL]INDOLE 4,7 DIONE; ANTINEOPLASTIC AGENT; CYSTEINE; ELECTROPHILE; ES 936; INDOLE DERIVATIVE; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL FREE SYSTEM; CELL STRAIN BXPC 3; CELL STRAIN MIA PACA 2; CELL STRAIN NCI 60; CELL STRAIN PANC 1; CLONOGENIC ASSAY; COLON CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; MELANOMA; MOUSE; NONHUMAN; NUDE MOUSE; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN TARGETING; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; CELL-FREE SYSTEM; DNA BREAKS, SINGLE-STRANDED; ENZYME INHIBITORS; FEMALE; HUMANS; INDOLEQUINONES; MICE; PANCREATIC NEOPLASMS; THIOREDOXIN-DISULFIDE REDUCTASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67649847825     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.055855     Document Type: Article

References (33)

1. Anestål K and Arnér ES (2003) Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine. J Biol Chem 278:15966-15972. (Pubitemid 36799715)
2. Arnér ES and Holmgren A (2006) The thioredoxin system in cancer. Semin Cancer Biol 16:420-426.
3. Beall HD, Winski S, Swann E, Hudnott AR, Cotterill AS, O'Sullivan N, Green SJ, Bien R, Siegel D, Ross D, et al. (1998) Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H: quinone oxidoreductase, and in vitro cytotoxicity. J Med Chem 41:4755-4766. (Pubitemid 28530452)
4. Bradshaw TD, Matthews CS, Cookson J, Chew EH, Shah M, Bailey K, Monks A, Harris E, Westwell AD, Wells G, et al. (2005) Elucidation of thioredoxin as a molecular target for antitumor quinols. Cancer Res 65:3911-3919. (Pubitemid 40616373)
5. Cassidy PB, Edes K, Nelson CC, Parsawar K, Fitzpatrick FA, and Moos PJ (2006) Thioredoxin reductase is required for the inactivation of tumor suppressor p53 and for apoptosis induced by endogenous electrophiles. Carcinogenesis 27:2538-2549. (Pubitemid 44884113)
6. Chew EH, Lu J, Bradshaw TD, and Holmgren A (2008) Thioredoxin reductase inhibition by antitumor quinols: a quinol pharmacophore effect correlating to antiproliferative activity. FASEB J 22:2072-2083. (Pubitemid 351811483)
7. Colucci MA (2007) Quinine-based inhibitors of NQO1. PhD Thesis, University of Nottingham, Nottingham, UK.
8. Colucci MA, Reigan P, Siegel D, Chilloux A, Ross D, and Moody CJ (2007) Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanismbased inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) activity. J Med Chem 50:5780-5789. (Pubitemid 350106033)
9. Cullen JJ, Hinkhouse MM, Grady M, Gaut AW, Liu J, Zhang YP, Weydert CJ, Domann FE, and Oberley LW (2003) Dicumarol inhibition of NADPH:quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism. Cancer Res 63:5513-5520. (Pubitemid 37139871)
10. Dehn DL, Siegel D, Zafar KS, Reigan P, Swann E, Moody CJ, and Ross D (2006) 5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione, a mechanism- based inhibitor of NAD(P)H:quinone oxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo. Mol Cancer Ther 5:1702-1709. (Pubitemid 44323238)
11. Everett SA, Naylor MA, Barraja P, Swann E, Patel KB, Stratford MR, Hudnott AR, Vojnovic B, Locke RJ, Wardman P, et al. (2001) Controlling the rates of reductively activated elimination from the (indol-3-yl)methyl position of indolequinones. J Chem Soc Perkin Trans 2 843-860. doi: 10.1039/b009652k (Pubitemid 33270817)
12. Fang J, Lu J, and Holmgren A (2005) Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity. J Biol Chem 280:25284-25290. (Pubitemid 40934623)
13. Friedlos F, Jarman M, Davies LC, Boland MP, Knox RJ (1992) Identification of novel reduced pyridinium derivatives as synthetic co-factors for the enzyme DT diaphorase (NAD(P)H dehydrogenase (quinone), EC 1.6.99.2). Biochem Pharmacol. 44: 25-31.
14. Ghaneh P, Costello E, and Neoptolemos JP (2007) Biology and management of pancreatic cancer. Gut 56:1134-1152.
15. Gromer S, Arscott LD, Williams CH Jr, Schirmer RH, and Becker K (1998) Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J Biol Chem 273:20096-20101. (Pubitemid 28377564)
16. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, and Thun MJ (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71-96.
17. Kirkpatrick DL, Kuperus M, Dowdeswell M, Potier N, Donald LJ, Kunkel M, Berggren M, Angulo M, and Powis G (1998) Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. Biochem Pharmacol 55:987-994. (Pubitemid 28167720)
18. Lewis A, Ough M, Li L, Hinkhouse MM, Ritchie JM, Spitz DR, and Cullen JJ (2004) Treatment of pancreatic cancer cells with dicumarol induces cytotoxicity and oxidative stress. Clin Cancer Res 10:4550-4558. (Pubitemid 38878899)
19. Lowry OH, Rosebrough NJ, Farr Al, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
20. Lu J, Chew EH, and Holmgren A (2007) Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci U S A 104:12288-12293. (Pubitemid 47206130)
21. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63. (Pubitemid 14203433)
22. Newsome JJ (2004) Heterocyclic quinones as new bioreductive delivery systems. PhD Thesis, University of Exeter, Exeter, UK.
23. Nordberg J, Zhong L, Holmgren A, and Arnér ES (1998) Mammalian thioredoxin reductase is irreversibly inhibited by dinitrohalobenzenes by alkylation of both the redox active selenocysteine and its neighboring cysteine residue. J Biol Chem 273:10835-10842. (Pubitemid 28204917)
24. Powis G and Montfort WR (2001) Properties and biological activities of thioredoxins. Annu Rev Pharmacol Toxicol 41:261-295.
25. Powis G, Wipf P, Lynch SM, Birmingham A, and Kirkpatrick DL (2006) Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase. Mol Cancer Ther 5:630-636.
26. Reigan P, Colucci MA, Siegel D, Chilloux A, Moody CJ, and Ross D (2007) Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells. Biochemistry 46:5941-5950. (Pubitemid 46799156)
27. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, Miyamae Y, Rojas E, Ryu JC, and Sasaki YF (2000) Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 35:206-221. (Pubitemid 30196665)
28. Urig S and Becker K (2006) On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin Cancer Biol 16:452-465. (Pubitemid 44780136)
29. Ward TH, Butler J, Shahbakhti H, and Richards JT (1997) Comet assay studies on the activation of two diaziridinylbenzoquinones in K562 cells. Biochem Pharmacol 53:1115-1121. (Pubitemid 27224257)
30. Winski SL, Faig M, Bianchet MA, Siegel D, Swann E, Fung K, Duncan MW, Moody CJ, Amzel LM, and Ross D (2001) Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches. Biochemistry 40:15135-15142. (Pubitemid 33151928)
31. Wipf P, Lynch SM, Birmingham A, Tamayo G, Jiménez A, Campos N, and Powis G (2004) Natural product based inhibitors of the thioredoxin-thioredoxin reductase system. Org Biomol Chem 2:1651-1658.
32. Witte AB, Anestål K, Jerremalm E, Ehrsson H, and Arnér ES (2005) Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med 39:696-703. (Pubitemid 41112110)
33. Yan C, Kepa JK, Siegel D, Stratford IJ, and Ross D (2008) Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1). Mol Pharmacol 74:1657-1665.